LONG BEACH, CA (February 1, 2005) – Pyro Pharmaceuticals, Inc. announced this week that its first patent, “A Method For Identifying a Compound For the Treatment of Microorganism Infections By Inhibiting Energy Storage and Utilization of Pathogens” (US patent # 6,852,485), will issue on February 8, 2005.

Pyro Pharmaceuticals is developing a new class of antibiotics against resistant and multi-drug resistant bacterial pathogens, according to Alan M. Schechter, chairman and chief executive officer.

The company said it has research collaborations with several academic research institutions. Two papers have been submitted based on the results that have been found from the collaborations.

Pyro Pharmaceuticals, Inc., an infectious disease company developing a novel class of antibiotics that are not inhibitors of DNA, RNA, protein, or cell wall synthesis, has been granted the first patent in its portfolio.